Gritstone Oncology Inc diskutieren

Gritstone bio, Inc. (NASDAQ: GRTS) is now covered by analysts at B. Riley. They set a "buy" rating and a $8.00 price target on the stock.

Gritstone bio, Inc. (NASDAQ: GRTS) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.

Gritstone bio, Inc. (NASDAQ: GRTS) had its price target raised by analysts at Piper Sandler from $6.00 to $7.00. They now have an "overweight" rating on the stock.

Gritstone bio, Inc. (NASDAQ: GRTS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.

Gritstone bio, Inc. (NASDAQ: GRTS) had its price target lowered by analysts at HC Wainwright from $7.00 to $4.00. They now have a "buy" rating on the stock.

Gritstone bio, Inc. (NASDAQ: GRTS) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $3.00 price target on the stock, down previously from $6.00.

Gritstone Oncology Inc. has been dealing with a class action lawsuit, which is never good news for a company. The recent articles highlight the legal troubles the company is facing, and this could weigh heavily on the stock price. While the company has some promising technology in the oncology space, the legal issues and uncertainty surrounding the business make me cautious about the stock at this time. I would wait on the sidelines until the legal situation is resolved before considering an investment. At the current price of $0.56, I believe the downside risk outweighs the potential upside, so I would rate this as a 'sell' and set a target price of $0.20. The company has a lot of work to do to regain investor confidence, and I would want to see clear signs of progress before becoming more bullish on the stock.

Gritstone Oncology Inc. has been facing a series of legal troubles, which have weighed heavily on the stock price. The company is currently embroiled in a class-action lawsuit, with several law firms reminding investors of the looming deadlines to join the lawsuit. This legal overhang creates a lot of uncertainty around the company's future, and I believe it's best to steer clear of the stock until the legal issues are resolved. The current price of $0.5415 seems too high given the risks, and I would recommend selling the stock and waiting for a clearer path forward before considering a re-entry. It's important to remember that legal battles can be unpredictable and often result in significant financial and reputational damage for the companies involved. In this case, I believe the risks outweigh the potential rewards, and it's prudent to take a step back and let the dust settle before making any investment decisions.

Based on the recent news and analyses, I have a rather negative outlook on Gritstone Oncology Inc. The company seems to be facing some legal troubles, with multiple class action lawsuits being filed against it. This could potentially be a major distraction and drag on the company's resources, making it harder for them to focus on their core business. Additionally, the stock price has been on a downward trend, currently trading at $0.611, which is significantly lower than its previous highs. While the company may be granting some inducement grants to new employees, this doesn't necessarily signal a strong outlook for the company's future. Given the legal issues and the downward price trend, I believe it might be prudent to consider selling this stock and looking for better investment opportunities elsewhere. Of course, this is just my personal assessment, and investors should always do their own research and consult with a financial advisor before making any investment decisions.

After reviewing the latest news and fundamental data on Gritstone Oncology Inc., I'm a bit concerned about the company's outlook. The recent class-action lawsuits and legal troubles are worrying, and I'm not confident in the company's ability to navigate these challenges effectively. The current stock price of $0.5955 seems a bit inflated, and I believe it could drop further to around $0.45 in the near term. While the company's efforts to develop innovative cancer treatments are admirable, the legal headwinds and potential financial implications make me hesitant to recommend a 'buy' rating at this time. I'd suggest keeping a close eye on the situation and reevaluating if the company can resolve the legal issues and demonstrate a clear path forward. For now, a 'sell' rating might be the prudent choice.

The recent news and developments surrounding Gritstone Oncology Inc (GRTS) give me pause. The company's announcement of inducement grants for a new employee, while not entirely unexpected, doesn't seem to move the needle much. What's more concerning are the multiple class action lawsuits that have been filed against GRTS by law firms on behalf of investors. These lawsuits allege securities fraud, and the looming deadlines for joining them suggest there could be some merit to the claims. As an investor, I can't help but wonder what skeletons might be lurking in GRTS's closet. Until the company can put these legal issues behind it and provide more clarity on its future prospects, I'm hesitant to invest. The current share price of $0.6045 seems optimistic, and I believe a more realistic target price would be around $0.40. For now, I'd recommend selling or avoiding this stock altogether.

Gritstone Oncology is facing some legal troubles, with multiple class action lawsuits being filed against the company. While the news about inducement grants to employees is positive, the ongoing legal issues raise concerns about the company's stability and future prospects. The current price of $0.6045 seems quite high given these uncertainties, and I believe there's a better chance of the stock price declining further rather than rebounding in the near term. As an investor, I would be cautious and consider selling my position to avoid potential further losses.

Gritstone Oncology Inc. (GRTS) is facing some legal troubles, with several class action lawsuits filed against the company. This, coupled with the company's recent stock price drop, gives me pause. While the company's technology and pipeline might be promising, the legal uncertainty and financial challenges make me cautious. I'd need to see some positive developments and a more stable financial footing before considering a buy. For now, I think it's best to steer clear and wait for the dust to settle. The target price of $0.50 reflects the risks and uncertainties surrounding the stock.